Phase 2 Study of Tafasitamab with Lenalidomide and Rituximab for Untreated Follicular and Marginal Zone Lymphoma

Inclusion Criteria

• Diagnosed with marginal zone lymphoma or CD20+ follicular lymphoma at stage 1, 2, or 3a.
• Have not received any previous systemic treatment for lymphoma.
• Need treatment due to:
  • Large tumor mass over 7 cm or multiple sites over 3 cm.
  • Symptoms like unexplained fever, night sweats, or significant weight loss.
  • Tumor affecting vital organs or causing issues like large spleen or fluid buildup.
  • High-risk follicular lymphoma based on specific scoring.
• Have adequate organ function as confirmed by recent tests.
• Agree to use effective birth control during and after treatment if of childbearing potential.
• Able to take preventive blood clot medication while on lenalidomide.
• Willing to provide written consent to participate in the study.

Exclusion Criteria

• Active hepatitis B or C infection.
• HIV positive.
• Previous use of lenalidomide.
• Other cancers unless disease-free for 5 years.
• Severe nerve damage.
• Uncontrolled illness or active infection.
• History of lymphoma in the brain or spinal cord.
• Not willing to take blood clot prevention medication.
• Recent serious blood clots.
• Pregnant or breastfeeding women.
• Women of childbearing potential must have negative pregnancy tests before starting lenalidomide and agree to regular pregnancy testing during treatment.